Navigation Links
Pharmasset Announces Two-for-One Forward Stock Split
Date:8/9/2011

PRINCETON, N.J., Aug. 9, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that its Board of Directors declared a two-for-one split of Pharmasset's common stock, par value $0.001 per share, in the form of a 100% common stock dividend.  Stockholders of record as of the close of business on August 22, 2011 will receive one additional share of common stock for each share then owned.  The distribution date for the new shares will be August 31, 2011.  There are currently approximately 37.7 million shares of common stock outstanding.  Upon completion of the stock split, there will be approximately 75.4 million shares of common stock outstanding.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections.  Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection.  Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication.  We currently have three clinical-stage product candidates advancing in trials in various populations.  Our pyrimidine, PSI-7977, an unpartnered uracil nucleotide analog, is currently under study in four Phase 2b trials in patients with HCV genotypes 1 through 6, including abbreviated duration interferon and interferon-free regimens.  Our purine, PSI-938, an unpartnered guanosine nucleotide analog, reported safety and efficacy data from 14 days of monotherapy as well as 14 days in combination with the pyrimidine, PSI-7977.  An SVR-endpoint study of the purine-pyrimidine combination is anticipated to begin in the third calendar quarter of 2011.  Mericitabine (RG7128) continues in three Phase 2b trials and one interferon-free trial being conducted through a strategic collaboration with Roche.

Contact
Richard E. T. Smith, Ph.D.
VP, Investor Relations and Corporate Communications
richard.smith@pharmasset.com
Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk that the stock split does not occur, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... , June 14, 2017  In 2016, ... Creative Startups pitch competition and came away with ... platform is described by Forbes as "entering the life ... Medical Association as teaching "empathy to medical professionals in ... startup was recently named a finalist for the Department ...
(Date:6/9/2017)... 9, 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders ... design, manufacture, sale and distribution of the AeroForm® Tissue ... of its commercial roll-out in the United ... than one hundred (100) medical institutions and health systems, ... a needle-free alternative for women who choose reconstructive surgery ...
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... , ... Leading dental clinicians, Drs. Ashlyn Price, Autumn Mayers and Ron Adelman, ... systems. With advanced digital images and modeling capabilities, the dentists identify all of the ... oral health for those who are missing teeth in Midlothian, VA. , ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in the ... finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations which ...
(Date:6/20/2017)... ... June 20, 2017 , ... BrightStar Care Centerville/South Dayton, a ... the Joint Commission, which accredits and certifies nearly 21,000 healthcare organizations and programs ... a symbol of quality that reflects an organization’s commitment to meeting certain performance ...
(Date:6/20/2017)... ... June 20, 2017 , ... The law firm of ... installation as the president of the DuPage County Bar Association’s Board of Directors. Cassioppi ... June 9 at the Drake in Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey ...
(Date:6/19/2017)... ... 19, 2017 , ... Intrinsic Clinical Systems announced it will ... actionable insights to improve health globally through the advancement of lifesaving medicines and ... faster, easier, and less painful. Attendees can visit Intrinsic’s booth showcasing its four ...
Breaking Medicine News(10 mins):